[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630422":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":29,"responsibleParty":38,"collaborators":22,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":22,"enrollmentInfo":50,"targetDuration":22,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":22,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Kaiser Clinic and Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Autologous SVF Duodenal Injection","EXPERIMENTAL","Participants with Type 2 Diabetes Mellitus will undergo abdominal adipose tissue harvesting using a 1210-nm diode laser-assisted selective photochemical stimulation technique (One-STEP™ method). The lipoaspirate will be processed by centrifugation without enzymatic digestion to isolate stromal vascular fraction (SVF) enriched with mesenchymal stem cells. The isolated SVF will be injected into the duodenal submucosa during the same surgical procedure. Participants will be followed for six months to assess metabolic outcomes and safety.",[13],"Biological: Autologous Adipose-Derived Stromal Vascular Fraction (SVF)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Autologous Adipose-Derived Stromal Vascular Fraction (SVF)","Autologous adipose tissue will be harvested using a 1210-nm diode laser-assisted liposuction technique (One-STEP™). The lipoaspirate will undergo double centrifugation without collagenase digestion to isolate stromal vascular fraction enriched with mesenchymal stem cells. The isolated SVF will be immediately injected into the duodenal submucosa during the same operative session.",[9],[21],"SVFD DM2",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Luiz Gustavo' Quadros, PhD","CONTACT","+55 17 98138-8737","gustavo_quadros@hotmail.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":22,"geoPoint":22,"contacts":22},"Kaiser Clinica","RECRUITING","São Jose Do Rio Preto","São Paulo","15.015-110","Brazil","BR",{"type":39,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100630422","autologous-svf-therapy-for-type-2-diabetes-100630422",false,"NCT07487467","Autologous SVF Therapy for Type 2 Diabetes","Evaluation of Autologous Adipose-Derived Stromal Vascular Fraction Obtained by 1210-nm Laser Photostimulation for the Treatment of Type 2 Diabetes Mellitus","LASER-DM2 Tria","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Both sexes\n* Diagnosis of Type 2 Diabetes Mellitus for less than 10 years\n* BMI ≥ 25 kg\u002Fm²\n* HbA1c between 7.5% and 9.5%\n* C-peptide \\> 1.0 nmol\u002FL\n* Use of metformin and\u002For pioglitazone, with or without sulfonylurea\n\nExclusion Criteria:\n\n* Type 1 Diabetes Mellitus or autoimmune diabetes\n* Positive anti-GAD antibodies\n* Pregnancy or breastfeeding\n* Use of insulin therapy\n* Use of SGLT2 inhibitors\n* Use of DPP-4 inhibitors\n* Use of GLP-1 receptor agonists\n* Unknown duration of diabetes","ALL","18 Years",{"count":51,"type":52},10,"ESTIMATED","INTERVENTIONAL",[55],"NA","This prospective clinical study aims to evaluate the safety and efficacy of autologous adipose-derived stromal vascular fraction (SVF), enriched with mesenchymal stem cells (ADSCs), for the treatment of Type 2 Diabetes Mellitus (T2DM).\n\nAdipose tissue will be harvested using a 1210-nm diode laser-assisted selective photochemical stimulation technique (One-STEP™ method), followed by centrifugation without enzymatic digestion. The isolated SVF will be injected endoluminally into the duodenal submucosa during the same surgical procedure.\n\nFive adult patients with T2DM will be followed for six months to assess metabolic control, pancreatic function, and quality of life outcomes.",[58],"Diabetes Mellitus, Type 2",[60,61,62,63,64],"Adipose-Derived Stem Cells","Stromal Vascular Fraction","Mesenchymal Stem Cells","GLP-1","Regenerative Medicine","2026-03-17",{"date":67,"type":68},"2026-03-23","ACTUAL",{"date":70,"type":68},"2025-01-20",{"date":72,"type":52},"2026-12-31",{"name":5,"class":6},1]